Fever following Covid‐19 vaccination in subjects with Brugada syndrome: Incidence and management.

Background: Fever is a potential side effect of the Covid‐19 vaccination. Patients with Brugada syndrome (BrS) have an increased risk of life‐threatening arrhythmias when experiencing fever. Prompt treatment with antipyretic drugs is suggested in these patients. Aim of the study: To evaluate the inc...

Full description

Bibliographic Details
Published in:Journal of Cardiovascular Electrophysiology Vol. 33; no. 8; pp. 1874 - 1880
Main Authors: Santoro, Francesco, Crea, Pasquale, Pellegrino, Pier Luigi, Cetera, Rosa, Gianfrancesco, Domenico, Abumayyaleh, Mohammad, Giuseppe, Dattilo, Allegra, Marta, Mancini, Nastasia, D'Arienzo, Girolamo, Mȕgge, Andreas, Aweimer, Assem, Bartolomucci, Francesco, Akin, Ibrahim, El‐Battrawy, Ibrahim, Brunetti, Natale Daniele
Format: research tables/charts Journal Article
Published: Wiley-Blackwell Aug2022
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=158655470&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 158655470
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10453873
        GSB
      jtl: Journal of Cardiovascular Electrophysiology
      issn: 10453873
      maglogo: Y
    pubinfo:
      dt: Aug2022
      vid: 33
      iid: 8
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        158655470
        157537149
        158655470
        158655470
        10.1111/jce.15596
        158655470
      ppf: 1874
      ppct: 6
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Fever following Covid‐19 vaccination in subjects with Brugada syndrome: Incidence and management.
      aug:
        au:
          Santoro, Francesco
          Crea, Pasquale
          Pellegrino, Pier Luigi
          Cetera, Rosa
          Gianfrancesco, Domenico
          Abumayyaleh, Mohammad
          Giuseppe, Dattilo
          Allegra, Marta
          Mancini, Nastasia
          D'Arienzo, Girolamo
          Mȕgge, Andreas
          Aweimer, Assem
          Bartolomucci, Francesco
          Akin, Ibrahim
          El‐Battrawy, Ibrahim
          Brunetti, Natale Daniele
        affil: Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
      sug:
        subj:
          COVID-19 Vaccines Administration and Dosage
          COVID-19 Vaccines Adverse Effects
          Fever Diagnosis
          Fever Prevention and Control
          Brugada Syndrome Physiopathology
          Pharmacological and Biological Treatments
          Treatment Outcomes
          Body Temperature
          Human
          Case Management
          Incidence
          Arrhythmia
          Adult
          Middle Age
          Descriptive Statistics
          Male
          Female
          Defibrillators, Implantable
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
          Female
      ab: Background: Fever is a potential side effect of the Covid‐19 vaccination. Patients with Brugada syndrome (BrS) have an increased risk of life‐threatening arrhythmias when experiencing fever. Prompt treatment with antipyretic drugs is suggested in these patients. Aim of the study: To evaluate the incidence and management of fever within 48 h from Covid‐19 vaccination among BrS patients. Methods: One hundred sixty‐three consecutive patients were enrolled in a prospective registry involving five European hospitals with a dedicated inherited disease ambulatory. Results: The mean age was 50 ± 14 years and 121 (75%) patients were male. Prevalence of Brugada electrocardiogram (ECG) pattern type‐1, ‐2, and ‐3 was 32%, 44%, and 24%, respectively. Twenty‐eight (17%) patients had an implantable cardioverter‐defibrillator (ICD). Fever occurred in 32 (19%) BrS patients after 16 ± 10 h from vaccination, with a peak of body temperature of 37.9° ± 0.5°. Patients with fever were younger (39 ± 13 vs. 48 ± 13 years, p =.04). No additional differences in terms of sex and cardiovascular risk factors were found between patients with fever and not. Twenty‐seven (84%) out of 32 patients experienced mild fever and five (16%) moderate fever. Pharmacological treatment with antipyretic drugs was required in 18 (56%) out of 32 patients and was associated with the resolution of symptoms. No patient required hospital admission and no arrhythmic episode was recorded in patients with ICD within 48 h after vaccination. No induced type 1 BrS ECG pattern and new ECG features were found among patients with moderate fever. Conclusion: Fever is a common side effect in BrS patients after the Covid‐19 vaccination. Careful evaluation of body temperature and prompt treatment with antipyretic drugs may be needed.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N